ZTS · 10-Q · 2026Q2

Zoetis Inc.

Filed 2026-08-06 · Healthcare · View original filing on EDGAR

Ranked Events

• Liquidity and Debt PositionImportance 70 · Surprise 56
  Cash and cash equivalents declined 40% to $1,476 million at June 30, 2026, from $2,450 million at December 31, 2025, while long-term debt remained nearly flat at $9,048 million versus $9,042 million. Working capital…
• Long-term Debt IssuanceImportance 64 · Surprise 42
  On August 18, 2025, Zoetis issued $850 million of 4.150% senior notes due 2028 and $1.00 billion of 5.000% senior notes due 2035. Net proceeds were used to redeem $600 million of 5.400% notes due 2025 and $750 million…
• Convertible Senior NotesImportance 64 · Surprise 42
  Zoetis completed a $2.0 billion private offering of 0.250% convertible senior notes on December 18, 2025, with maturity on June 15, 2029 and an initial conversion price of approximately $148.20 per share. Net proceeds…
• Macroeconomic Consumer PressureImportance 60 · Surprise 40
  U.S. companion-animal revenue declined by $240 million, or 11%, in the six months ended June 30, 2026. Zoetis attributed the decline partly to softer end-market demand, heightened competition and macroeconomic-driven…
• Competition and Pricing PressureImportance 60 · Surprise 40
  U.S. companion animal revenue declined 11% in both the three- and six-month periods ended June 30, 2026, primarily because of softer end-market demand and an increasingly competitive landscape. The key dermatology…
• Revolving Credit FacilityImportance 58 · Surprise 42
  In August 2025, Zoetis entered into a $1.25 billion senior unsecured revolving credit facility that expires in August 2030. The company may increase the facility to $1.75 billion subject to conditions, and the maximum…
• International Segment GrowthImportance 54 · Surprise 40
  International segment revenue increased 12% to $2,322 million in the six months ended June 30, 2026, with operational revenue up 7% or $141 million. Operational growth included $72 million from companion animal…
• Capital Return ProgramImportance 52 · Surprise 42
  Zoetis’ August 2024 board authorization permits up to $6 billion of common-stock repurchases, with $1.3 billion remaining as of June 30, 2026. During the first six months of 2026, the company repurchased 11.0 million…
• Revenue Performance and MixImportance 49 · Surprise 32
  Six-month revenue increased 1% to $4,730 million from $4,672 million, while operational revenue declined 1% because key-franchise volume fell approximately 3%. Price growth of approximately 1% and volume growth from…
• Geographic Market CommentaryImportance 48 · Surprise 40
  The U.S. market weakened, with segment revenue down 7% in both the quarter and year-to-date period, driven by companion animal products despite livestock growth. International revenue increased 8% in the quarter and…
• FX / Currency ImpactImportance 43 · Surprise 32
  For the six months ended June 30, 2026, approximately 46% of Zoetis’s $4,730 million revenue was denominated in foreign currencies, while approximately 54% was in U.S. dollars. Exposure includes the Australian dollar,…
• Disease Outbreak ImpactImportance 40 · Surprise 42
  Zoetis stated that animal disease outbreaks can reduce demand for livestock products by lowering regional or global sales of animal-derived food products and restricting exports. In the six months ended June 30, 2026,…
• Supply Chain ConstraintsImportance 38 · Surprise 24
  Improved supply availability supported higher U.S. cattle product sales during the quarter and year-to-date period. Cattle demand was additionally elevated in response to the New World screwworm outbreak. Zoetis…
• Product Launch and TransitionImportance 38 · Surprise 60
  Zoetis launched Lenivia and Portela in international markets as long-acting monoclonal antibody pain products. The launches contributed to increased demand for small animal diagnostics and monoclonal antibody pain…
• ERP Transformation and ComplianceImportance 37 · Surprise 42
  Effective January 1, 2026, Zoetis eliminated the one-month reporting lag for International Subsidiaries as part of a multi-year enterprise resource planning (ERP) transition. The company described the broader…
• Trade Policy and TariffsImportance 37 · Surprise 42
  Starting in early 2025, the United States announced additional tariffs on goods imported from numerous countries, including measures affecting trade relations with China, Canada and the European Union. Multiple nations…
• U.S. Segment Revenue DeclineImportance 37 · Surprise 32
  U.S. segment revenue decreased 7% in the three and six months ended June 30, 2026, with companion animal declines of $132 million and $240 million, respectively, partially offset by livestock increases of $42 million…
• Headcount / RestructuringImportance 37 · Surprise 42
  Restructuring charges in the three and six months ended June 30, 2026 were primarily driven by employee termination costs under Zoetis’s comprehensive cost and productivity program. The six-month period also included…
• Operating Cash Flow TrendsImportance 31 · Surprise 32
  Net cash provided by operating activities decreased 6% to $1,056 million in the six months ended June 30, 2026, from $1,120 million in the prior-year period. The decline reflected lower net income adjusted by non-cash…
• Operating Expense TrendsImportance 31 · Surprise 32
  Six-month SG&A expense decreased 1%, or $8 million, primarily because of lower depreciation, lower certain significant items and lower charitable contributions. Six-month R&D expense increased 8%, or $25 million, due…

Revenue by Product (in millions)

Revenue by Geography (in millions)